...
首页> 外文期刊>Asian Journal of Pharmaceutical and Clinical Research >A CORRELATION BETWEEN THYROID STIMULATING HORMONE AND BODY MASS INDEX IN WOMEN WITH SUBCLINICAL HYPOTHYROIDISM IN NCR
【24h】

A CORRELATION BETWEEN THYROID STIMULATING HORMONE AND BODY MASS INDEX IN WOMEN WITH SUBCLINICAL HYPOTHYROIDISM IN NCR

机译:NCR患者甲状腺激素刺激激素与身体质量指数的相关性

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Objective: Weight gain is a characteristic feature of hypothyroidism. People with subclinical hypothyroidism (SCH) are also characterized by the same is still unclear. Methods: Height and weight were calculated of SCH women as well as normal healthy adult women. Body mass index (BMI) was calculated as per WHO guidelines. The thyroid stimulating hormone (TSH), FT4, and T3 were measured by Enzyme-Linked Immunosorbent Assay technique. Results: Thyroid profile (TSH and T3) was significantly (<0.05) different between subclinical hypothyroidism women and normal women. Women with subclinical hypothyroidism were having higher TSH (13.01±4.41 vs. 2.61±0.79) compared with normal healthy control group along with different T3 (0.94±0.17±1.09±0.26) between the groups. The serum concentration of FT4 was not significant between the groups. The body mass index, higher (28.81±3.47 vs. 22.62±1.57) in subclinical hypothyroidism women, was highly significant (<0.001). BMI was positively correlated with TSH in SCH (0.36) group as well as normal control (0.50) group. The correlation was significant (<0.05) in both the groups. Conclusion: People with subclinical hypothyroidism were characterized by increased weight gain. Thereby it is concluded that Thyroid Stimulating Hormone affects the Body Mass Index in SCH women. Our result suggests that estimation of thyroid profile, also within the normal range, could be one of several factors acting in concert to determine body weight. However, this parallel increase in BMI due to weight gain along with increase in TSH may further leads to overt hypothyroidism if left untreated. Obesity itself could produce various metabolic disorders in coming future.
机译:目的:体重增加是甲状腺功能减退的特征。亚临床甲状腺功能减退症(SCH)的人是否也具有相同特征尚不清楚。方法:计算SCH女性以及正常健康成年女性的身高和体重。根据WHO指南计算体重指数(BMI)。通过酶联免疫吸附测定技术测量甲状腺刺激激素(TSH),FT4和T3。结果:亚临床甲状腺功能减退症妇女与正常妇女的甲状腺特征(TSH和T3)显着(<0.05)不同。与正常健康对照组相比,亚临床甲状腺功能减退症的女性的TSH较高(13.01±4.41比2.61±0.79),而两组之间的T3也不同(0.94±0.17±1.09±0.26)。两组之间的FT4血清浓度不显着。亚临床甲状腺功能减退症妇女的体重指数较高(28.81±3.47 vs. 22.62±1.57),非常显着(<0.001)。 SCH(0.36)组和正常对照组(0.50)组的BMI与TSH呈正相关。两组之间的相关性均显着(<0.05)。结论:亚临床甲状腺功能减退症患者的特点是体重增加。从而得出结论,促甲状腺激素影响SCH妇女的体重指数。我们的结果表明,甲状腺分布的估计值(也在正常范围内)可能是确定体重的几个因素之一。但是,如果不加以治疗,由于体重增加而导致的BMI的平行增加以及TSH的增加可能进一步导致明显的甲状腺功能减退。肥胖本身可能在未来出现各种代谢异常。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号